IVERIC bio (FRA:O2T) Debt-to-Equity : 0.21 (As of Mar. 2023)

View and export this data going back to 2013. Start your Free Trial

What is IVERIC bio Debt-to-Equity?

IVERIC bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was €0.72 Mil. IVERIC bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was €90.59 Mil. IVERIC bio's Total Stockholders Equity for the quarter that ended in Mar. 2023 was €445.56 Mil. IVERIC bio's debt to equity for the quarter that ended in Mar. 2023 was 0.20.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for IVERIC bio's Debt-to-Equity or its related term are showing as below:

FRA:O2T' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.21
Current: 0.21

During the past 12 years, the highest Debt-to-Equity Ratio of IVERIC bio was 0.21. The lowest was 0.00. And the median was 0.01.

FRA:O2T's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs FRA:O2T: 0.21

IVERIC bio Debt-to-Equity Historical Data

The historical data trend for IVERIC bio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IVERIC bio Debt-to-Equity Chart

IVERIC bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.18

IVERIC bio Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Equity	Get a 7-Day Free Trial															-	0.01	0.19	0.18	0.21

Competitive Comparison of IVERIC bio's Debt-to-Equity

For the Biotechnology subindustry, IVERIC bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IVERIC bio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IVERIC bio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where IVERIC bio's Debt-to-Equity falls into.

IVERIC bio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

IVERIC bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.122	+	91.171)	/	504.716
	=	0.18

IVERIC bio's Debt to Equity Ratio for the quarter that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.723	+	90.586)	/	445.561
	=	0.20

IVERIC bio (FRA:O2T) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

IVERIC bio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of IVERIC bio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

IVERIC bio (FRA:O2T) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IVERIC bio Inc (FRA:O2T) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 Sylvan Way, Parsippany, New Jersey, USA, 07054

Website

https://www.ivericbio.com

IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases, or IRDs.

IVERIC bio (FRA:O2T) Headlines

No Headlines